Cardiovascular disease in type 1 diabetes: A review of epidemiological data and underlying mechanisms

Area of Science:

• Endocrinology
• Cardiology
• Immunology

Background:

• Cardiovascular disease (CVD) is highly prevalent and a leading cause of mortality in type 1 diabetes (T1D) patients.
• CVD develops earlier in T1D patients, reducing life expectancy by at least 11 years, with earlier onset exacerbating the risk.
• The precise factors driving accelerated atherosclerosis and CVD in T1D remain incompletely understood.

Purpose of the Study:

• To elucidate the multifaceted factors contributing to the elevated cardiovascular disease risk in type 1 diabetes.
• To explore the roles of chronic hyperglycemia, glucose variability, and other metabolic and immune factors in T1D-associated CVD.
• To identify potential therapeutic targets for mitigating CVD in the T1D population.

Main Methods:

• Review and synthesis of existing literature on cardiovascular complications in type 1 diabetes.
• Analysis of the impact of chronic hyperglycemia, oxidative stress, vascular inflammation, and endothelial dysfunction.
• Investigation of the roles of diabetic nephropathy, cardiac autonomic neuropathy, and lipoprotein abnormalities.
• Consideration of emerging factors such as glucose variability, immune system dysfunction, and obesity in T1D.

Main Results:

• Chronic hyperglycemia directly promotes oxidative stress, vascular inflammation, monocyte adhesion, arterial thickening, and endothelial dysfunction.
• Diabetic nephropathy, cardiac autonomic neuropathy, and abnormal lipoprotein profiles are significantly associated with increased CVD risk in T1D.
• Hypoglycemia and glucose variability may exacerbate CVD through similar inflammatory and endothelial dysfunction pathways.
• Even well-controlled T1D patients exhibit increased CVD risk, suggesting contributions from factors beyond traditional risk factors and hyperglycemia.

Conclusions:

• Cardiovascular disease in T1D is driven by a complex interplay of factors including chronic hyperglycemia, glucose variability, metabolic abnormalities, and potentially immune system dysfunction.
• These factors collectively promote atherosclerosis and endothelial dysfunction, leading to premature CVD and reduced life expectancy in T1D patients.
• Addressing these multifaceted risks, including those present even in well-controlled T1D, is crucial for improving cardiovascular outcomes and longevity in this population.